Capsugel Installs New Encapsulation Unit for DPI Applications at Bend, Oregon Facility

March 30, 2017
Pharmaceutical Technology Editors
PTSM: Pharmaceutical Technology Sourcing and Management
Volume 12, Issue 4

The newly installed Harro Hӧfliger encapsulation unit expands Capsugel’s clinical- and commercial-scale capacity for dry powder inhalation projects.

Capsugel has expanded its late-stage inhalation capabilities to advance dry powder inhalation (DPI) concepts through late-stage clinical trial and commercial production. A new Harro HÓ§fliger Modu-C MS encapsulation unit has been installed and validated at its Bend, Ore. facility that includes specialized drum-dosing technology for DPI development projects using spray-dry processing.

The equipment has an operational capacity of more than 72,000 capsules per hour. The technology provides 100% monitoring of dosed powder mass, fill weight ranges between 5 mg and 50 mg, and dose accuracy of <3% relative standard deviation.

The unit complements Capsugel’s Xcelodose 600S equipment that supports capsule filling for Phase 1 and Phase 2 trials. Capsugel’s capabilities for DPI formulations include spray drying for all clinical phases and commercial manufacturing, formulation development and scale-up, phase-appropriate encapsulation and full aerosol analytical capabilities in development and GMP.

Source: Capsugel